Holen Sie sich die Stockscreener-App
1.42
26.79%
0.30
Schlusskurs vom Vortag:
$1.12
Offen:
$1.13
24-Stunden-Volumen:
5.76M
Relative Volume:
9.33
Marktkapitalisierung:
$47.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-0.4343
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+114.70%
1M Leistung:
+140.51%
6M Leistung:
+446.15%
1J Leistung:
-49.29%
1-Tages-Spanne:
$1.06
$1.5684
1-Wochen-Bereich:
$0.612
$1.5684
52-Wochen-Spanne:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Vergleichen Sie RLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.54 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.5778 | 115.14M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.3175 | 651.68M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.22 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
43.41 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Leading vs lagging indicators on Relmada Therapeutics Inc. performance2025 Analyst Calls & Verified Entry Point Detection - Newser
Using R and stats models for Relmada Therapeutics Inc. forecasting2025 AllTime Highs & Technical Confirmation Alerts - Newser
Can machine learning forecast Relmada Therapeutics Inc. recoveryJuly 2025 Opening Moves & Safe Entry Zone Tips - Newser
How sentiment analysis helps forecast Relmada Therapeutics Inc.Jobs Report & Community Consensus Trade Signals - Newser
Can Relmada Therapeutics Inc. be recession proofQuarterly Portfolio Review & Capital Efficiency Focused Ideas - خودرو بانک
What is Relmada Therapeutics Inc. s revenue forecastJuly 2025 Pullbacks & Short-Term High Return Ideas - خودرو بانک
Can momentum traders help lift Relmada Therapeutics Inc.Portfolio Return Report & Free Accurate Trade Setup Notifications - Newser
Relmada Therapeutics executive purchases 55,000 shares on open market - Investing.com
Relmada Therapeutics CMO Purchases 55,000 Shares - TipRanks
What the charts say about Relmada Therapeutics Inc. today2025 Historical Comparison & Weekly Top Gainers Trade List - Newser
What’s next for Relmada Therapeutics Inc. stock priceMarket Performance Report & Real-Time Buy Zone Alerts - Newser
Relmada Therapeutics (RLMD): Is the 91% Response Rate in Bladder Cancer a Catalyst for a Phase 3-Driven Bull Run? - AInvest
Will Relmada Therapeutics Inc. see short term momentumOptions Play & Low Volatility Stock Recommendations - Newser
Is now a turning point for Relmada Therapeutics Inc.Swing Trade & Daily Stock Momentum Reports - Newser
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study - Yahoo Finance
Is Relmada Therapeutics Inc.’s growth already priced inQuarterly Growth Report & Fast Moving Trade Plans - kpenews.com
Should value investors consider Relmada Therapeutics Inc.2025 Year in Review & Safe Entry Momentum Stock Tips - خودرو بانک
Is Relmada Therapeutics Inc. still worth holding after the dip2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Real time scanner hits for Relmada Therapeutics Inc. explained2025 Volatility Report & Risk Managed Investment Signals - Newser
Analyzing recovery setups for Relmada Therapeutics Inc. investorsQuarterly Investment Review & Weekly High Potential Alerts - Newser
What MACD signals say about Relmada Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - Newser
Unraveling the Sudden Surge in Relmada Therapeutics (RLMD.O): What's Really Behind the 44.5% Intraday Jump? - AInvest
Relmada Therapeutics (RLMD.O) Surges 44.5% Intraday: Unraveling the Hidden Driver - AInvest
RLMD.O Soars 44.5%—What’s Behind the Surge? - AInvest
3 Promising Penny Stocks With Market Caps Under $400M - Yahoo Finance
Is a relief rally coming for Relmada Therapeutics Inc. holdersFed Meeting & Risk Managed Investment Entry Signals - Newser
Will Relmada Therapeutics Inc. continue its uptrendPortfolio Profit Report & Weekly Top Performers Watchlists - Newser
Price momentum metrics for Relmada Therapeutics Inc. explainedWeekly Market Outlook & Expert Verified Stock Movement Alerts - Newser
Analyzing drawdowns of Relmada Therapeutics Inc. with statistical toolsQuarterly Profit Review & AI Powered Market Trend Analysis - Newser
Can technical indicators confirm Relmada Therapeutics Inc.’s reversalJuly 2025 Pullbacks & Daily Market Momentum Tracking - Newser
Will Breakout in Relmada Therapeutics Inc. Sustain Through Next Week getLinesFromResByArray error: size == 0 - kangso.co.kr
Best data tools to analyze Relmada Therapeutics Inc. stockInflation Watch & Low Volatility Stock Recommendations - Newser
Relmada Therapeutics Stock (RLMD) Opinions on Clinical Trial Results and Insider Buying - Quiver Quantitative
AI Tools Suggest Relmada Therapeutics Inc. May Outperform This Week2025 Momentum Check & Consistent Profit Trade Alerts - beatles.ru
Is it too late to sell Relmada Therapeutics Inc.Rate Hike & Weekly Watchlist of Top Performers - Newser
Analyzing Relmada Therapeutics Inc. with multi timeframe chartsStop Loss & Fast Momentum Entry Tips - Newser
Historical volatility pattern of Relmada Therapeutics Inc. visualizedPortfolio Performance Report & Pattern Based Trade Signal System - Newser
Is Relmada Therapeutics Inc. impacted by rising ratesJuly 2025 Levels & Real-Time Stock Price Movement Reports - kpenews.com
Using portfolio simulators with Relmada Therapeutics Inc. includedJuly 2025 Big Picture & High Return Stock Watch Alerts - Newser
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):